## Early-Stage Laryngeal Carcinoma: Treatment Strategy ### TNM Staging in This Case **Key Point:** This lesion meets criteria for **T1N0M0 (Stage I)**: - ≤2 cm, confined to vocal cord, no anterior commissure involvement, no arytenoid involvement → **T1** - No regional lymph node involvement → **N0** - No distant metastases → **M0** ### Treatment Paradigm for Stage I Laryngeal Cancer ```mermaid flowchart TD A[Stage I Laryngeal SCC]:::outcome --> B{Treatment Goal}:::decision B -->|Voice Preservation| C[Transoral Laser Microsurgery<br/>OR<br/>Radiation Therapy]:::action B -->|Curative Intent| D[Either modality acceptable]:::action C --> E[Cure rates 85-95%]:::outcome D --> F[Comparable oncologic outcomes]:::outcome ``` | Treatment Modality | Indications | Advantages | Disadvantages | |-------------------|-------------|-----------|---------------| | **TLM** | T1–T2, good performance status | Single procedure, voice quality, cost-effective, no long-term RT effects | Requires expertise, difficult access in some patients | | **Radiation Therapy** | T1–T2, all ages | Non-invasive, treats entire larynx, suitable for poor surgical candidates | 6–7 weeks treatment, late toxicity, second malignancy risk | | **CCRT** | T3–T4 or N+ disease | Organ preservation in advanced disease | Not indicated for Stage I; unnecessary toxicity | | **Laryngectomy** | T4, fixed cord, cartilage invasion | Definitive, no recurrence risk | Voice loss, permanent tracheostomy, poor QoL | ### Why TLM or RT for This Patient? **High-Yield:** For **Stage I disease**, both TLM and RT offer: - **Cure rates 85–95%** - **Voice preservation** - **Comparable oncologic outcomes** - **No need for chemotherapy** (no nodal involvement, no advanced local disease) **Clinical Pearl:** The choice between TLM and RT depends on: - Patient age and comorbidities - Lesion accessibility - Patient preference - Institutional expertise Both are **equally valid** first-line options for Stage I laryngeal cancer. ### Why Not Other Treatments? - **CCRT (Option A):** Reserved for Stage III–IV disease or N+ disease. Stage I disease does not require chemotherapy; adds toxicity without benefit. - **Total Laryngectomy (Option C):** Causes permanent voice loss and tracheostomy dependence. Inappropriate for Stage I where voice-preserving options cure >85% of patients. - **Neoadjuvant Chemotherapy (Option D):** Not indicated for Stage I disease. Neoadjuvant therapy is used in T4 or N2–N3 disease to enable organ preservation. ### Laryngeal Preservation Principle **Mnemonic:** **LASER** — **L**aryngeal **A**dvanced **S**tage requires **E**ither **R**adiation or surgery (not chemo alone) - Stage I–II → TLM or RT (voice-preserving) - Stage III–IV → CCRT or TLM + RT (organ preservation) - Salvage → Laryngectomy (if preservation fails) [cite:Harrison 21e Ch 85; NCCN Head and Neck Cancer Guidelines 2023] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.